Beschreibung
Ramatercept (ACE-031) is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy[1][2][3]. IC50 & Target
soluble activin receptor 2, ACVR2[2] In Vivo
Ramatercept (ACE-031) (10 mg/kg; s.c.; three times a week for 5 weeks) significantly increases the muscle mass of mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Klinische Studie
Application
ELISA, FACS, Functional assay Conjugated
Unconjugated Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline. Molekulargewicht
77.24 kDa CAS. Nr.
1169766-01-1 Appearance
Liquid Color
Colorless to light yellow SMILES
[Ramatercept] Versand
Shipping with dry ice. Formulation
Please refer to the lot-specific COA for specific buffer information. Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis. Format
[ACVR2B (activin A receptor type 2B, ActR-IIB, ActRIIB)]2-IGHG1 Fc (Fragment constant) Reinheit & Dokumentation
Purity: ≥99.0%
Select Batch:
SDS (251 KB)
COA (232 KB) SDS-PAGE (585 KB) SEC-HPLC (649 KB)
Inhibitory Antibodies User Guide (603 KB) Verweise
[1]. Fariello R G, et al. A novel Biological (FOX-115) improves endurance of motor performances in old mice (P2. 4-033)[J]. 2019.
[2]. Feike Y, et al. Advances in research on pharmacotherapy of sarcopenia. Aging Med (Milton). 2021 Aug 9;4(3):221-233. [Content Brief]
[3]. Louvel É. Dopage: nouveaux médicaments influant sur la biogenèse musculaire et mitochondriale[J]. 2019.